Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI – Get Rating) major shareholder Global Strategic Fund I. Venbio sold 399,923 shares of the business’s stock in a transaction dated Tuesday, April 19th. The stock was sold at an average price of $10.42, for a total transaction of $4,167,197.66. Following the sale, the insider now directly owns 3,273,451 shares in the company, valued at $34,109,359.42. The sale was disclosed in a legal filing with the SEC, which is available through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of CMPI remained flat at $$10.39 during trading hours on Thursday. 241,103 shares of the stock traded hands, compared to its average volume of 95,918. The company has a 50-day moving average price of $3.52 and a 200 day moving average price of $3.40. The company has a market cap of $224.75 million, a P/E ratio of -3.66 and a beta of 0.61. Checkmate Pharmaceuticals, Inc. has a 52-week low of $2.00 and a 52-week high of $10.45.
Checkmate Pharmaceuticals (NASDAQ:CMPI – Get Rating) last announced its quarterly earnings data on Tuesday, March 29th. The company reported ($0.62) earnings per share for the quarter. Analysts forecast that Checkmate Pharmaceuticals, Inc. will post -3.14 EPS for the current fiscal year.
CMPI has been the subject of a number of recent research reports. Zacks Investment Research raised shares of Checkmate Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday. BTIG Research cut shares of Checkmate Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday.
About Checkmate Pharmaceuticals (Get Rating)
Checkmate Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma.
- Get a free copy of the StockNews.com research report on Checkmate Pharmaceuticals (CMPI)
- NextEra Energy Offers a Long-Term Gain if You Can Tolerate Short-Term Pain
- Steel Dynamics Scales New Heights On Record Results
- Tesla (NASDAQ: TSLA) Stock Hits Four Figures Once Again
- The Institutions Are Driving Knight-Swift Transportation
- 3 Legendary Low-Beta Stocks Set to Outperform
Receive News & Ratings for Checkmate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkmate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.